{"id":510709,"date":"2021-07-08T06:53:07","date_gmt":"2021-07-08T10:53:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/"},"modified":"2021-07-08T06:53:07","modified_gmt":"2021-07-08T10:53:07","slug":"novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/","title":{"rendered":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>NovaBay Pharmaceuticals to Participate in Two July Investment Conferences<\/b><\/p>\n<p>EMERYVILLE, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.novabay.com%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=NovaBay%26%23174%3B+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=7b21220e2f74fc69d47dee2716c68ae8\">NovaBay<sup>\u00ae<\/sup> Pharmaceuticals, Inc<\/a>. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova<sup>\u00ae<\/sup> for the eye care market and CelleRx<sup>\u00ae<\/sup> for the beauty market, announces that management will participate at the upcoming investment conferences:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li><b>Ladenburg Thalmann Virtual Healthcare Conference <\/b>being held July 13-14. Management will present a company overview on July 14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of the presentation will be available on the <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnovabay.com%2Finvestors%2Fevents%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=NovaBay+website&amp;index=2&amp;md5=ed8d7990ab6e6390091bdaa822d9d14a\">NovaBay website<\/a>.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li><b>A.G.P.\u2019s Virtual MedTech Summer Conference<\/b> featuring one-on-one investor meetings on July 29.\n<\/li>\n<\/ul>\n<p>\n\u201cWe are addressing extremely large markets with our two differentiated products, Avenova and CelleRx, and look forward to sharing details of our growth strategy at these conferences,\u201d said Justin Hall, CEO of NovaBay Pharmaceuticals. \u201cWe have set record Avenova unit sales for the past three consecutive quarters, while barely tapping the dry eye market we estimate at 16 million Americans. We also launched our breakthrough product CelleRx late last year, bringing a new level of clinical research and innovation to the beauty category. We are currently rolling out new, sophisticated media campaigns for both Avenova and CelleRx aimed at attracting new customers and encouraging repeat usage.\u201d\n<\/p>\n<p>\n\u201cWe are also actively evaluating opportunities to support profitable growth through acquisition or licensing of ophthalmic and skincare products,\u201d he added. \u201cOur experienced commercial organization, balance sheet and established industry relationships all give us confidence that we are positioned to pursue new sources of revenue in order to increase shareholder value.\u201d\n<\/p>\n<p><b>About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics<sup>\u00ae<\/sup><\/b><\/p>\n<p>\nNovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on high-quality, differentiated, anti-infective consumer products: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avenova.com%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=Avenova%26%23174%3B&amp;index=3&amp;md5=516a82a82b3a397fa58adc1dc58a50be\">Avenova<sup>\u00ae<\/sup><\/a>, the premier antimicrobial lid and lash spray, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cellerx.com%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=CelleRx%26%23174%3B+Clinical+Reset%26%238482%3B%2C&amp;index=4&amp;md5=83a61b3d6a14c1455c8233bde49321d3\">CelleRx<sup>\u00ae<\/sup> Clinical Reset\u2122,<\/a> a breakthrough product in the beauty category, and NeutroPhase<sup>\u00ae<\/sup> Skin and Wound Cleanser for wound healing. NovaBay\u2019s products are formulated with its patented, pure, stable, pharmaceutical-grade hypochlorous acid that replicates the antimicrobial chemicals used by white blood cells to fight infection. NovaBay\u2019s hypochlorous acid products do not cause stinging or irritation, are non-toxic and non-sensitizing, making them completely safe for regular use. Avenova is the only commercial hypochlorous acid lid and lash spray product clinically proven to reduce bacterial load on ocular skin surfaces, thus effectively addressing the underlying cause of bacterial dry eye.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nExcept for historical information herein, matters set forth in this press release are forward-looking within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management\u2019s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings, potential future product offerings, and any future revenue that may result from selling these products, as well as generally the Company\u2019s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company\u2019s products will not be as large as expected, the Company\u2019s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company\u2019s cash needs, the effect on sales and potential reputational damage resulting from decisions or actions taken by regulators, including Warning Letters issued by the FDA, and any other potential regulatory problems that may arise. Other risks relating to NovaBay\u2019s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay\u2019s latest Form 10-Q\/K filings with the Securities and Exchange Commission, especially under the heading \u201cRisk Factors.\u201d The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.\n<\/p>\n<p><b><span class=\"bwuline\">Socialize and Stay informed on NovaBay\u2019s progress<br \/>\n<br \/><\/span><\/b>Like us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fnovabaypharma%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=48a81f3a50aa5a5e17f75a3d64cf04f9\">Facebook<br \/>\n<\/a><br \/>Follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FNovaBay&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=5b8f5786626710f6501aa5dc3dbab7d6\">Twitter<br \/>\n<\/a><br \/>Connect with NovaBay on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fnovabay-pharmaceuticals%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=e2bc34082808888a0de1e2645965ae5a\">LinkedIn<br \/>\n<\/a><br \/>Visit NovaBay\u2019s <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnovabay.com%2F&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=Website&amp;index=8&amp;md5=6aa0de3cccc8323e3eba5b0d32f190c5\">Website<\/a><\/p>\n<p><b><span class=\"bwuline\">Avenova Purchasing Information<br \/>\n<br \/><\/span><\/b>For NovaBay Avenova purchasing information:<br \/>\n<br \/>Please call 800-890-0329 or email <a rel=\"nofollow\" href=\"mailto:sales@avenova.com\">sales@avenova.com<\/a>.<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.avenova.com&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=Avenova.com&amp;index=9&amp;md5=f09d8d2953a231cb361e419eb590bb64\">Avenova.com<\/a><\/p>\n<p><b><span class=\"bwuline\">CelleRx Clinical Reset Purchasing Information<br \/>\n<br \/><\/span><\/b>For NovaBay CelleRx Clinical Reset purchasing information<br \/>\n<br \/>Please call 877-CELLERX<br \/>\n<br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.CelleRx.com&amp;esheet=52456137&amp;newsitemid=20210708005029&amp;lan=en-US&amp;anchor=www.CelleRx.com&amp;index=10&amp;md5=426dda268740fb32e8c4764263540374\">www.CelleRx.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210708005029\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210708005029\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">NovaBay Contact<br \/>\n<\/span><\/b><br \/>Justin Hall<br \/>\n<br \/>Chief Executive Officer and General Counsel<br \/>\n<br \/>510-899-8800<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jhall@novabay.com\">jhall@novabay.com<\/a><\/p>\n<p><b><span class=\"bwuline\">Investor Contact<br \/>\n<\/span><\/b><br \/>LHA Investor Relations<br \/>\n<br \/>Jody Cain<br \/>\n<br \/>310-691-7100<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jcain@lhai.com\">jcain@lhai.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Cosmetics Retail Health Infectious Diseases Pharmaceutical Optical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>NovaBay Pharmaceuticals to Participate in Two July Investment Conferences EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae for the eye care market and CelleRx\u00ae for the beauty market, announces that management will participate at the upcoming investment conferences: Ladenburg Thalmann Virtual Healthcare Conference being held July 13-14. Management will present a company overview on July 14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of the presentation will be available on the NovaBay website. A.G.P.\u2019s Virtual MedTech Summer Conference featuring one-on-one investor meetings on July 29. \u201cWe are addressing extremely large markets with our two differentiated products, Avenova and CelleRx, and look forward to sharing details of our growth strategy &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NovaBay Pharmaceuticals to Participate in Two July Investment Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510709","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NovaBay Pharmaceuticals to Participate in Two July Investment Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae for the eye care market and CelleRx\u00ae for the beauty market, announces that management will participate at the upcoming investment conferences: Ladenburg Thalmann Virtual Healthcare Conference being held July 13-14. Management will present a company overview on July 14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of the presentation will be available on the NovaBay website. A.G.P.\u2019s Virtual MedTech Summer Conference featuring one-on-one investor meetings on July 29. \u201cWe are addressing extremely large markets with our two differentiated products, Avenova and CelleRx, and look forward to sharing details of our growth strategy &hellip; Continue reading &quot;NovaBay Pharmaceuticals to Participate in Two July Investment Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-08T10:53:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences\",\"datePublished\":\"2021-07-08T10:53:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/\"},\"wordCount\":837,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/\",\"name\":\"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-08T10:53:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/","og_locale":"en_US","og_type":"article","og_title":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences - Market Newsdesk","og_description":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences EMERYVILLE, Calif.&#8211;(BUSINESS WIRE)&#8211;NovaBay\u00ae Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova\u00ae for the eye care market and CelleRx\u00ae for the beauty market, announces that management will participate at the upcoming investment conferences: Ladenburg Thalmann Virtual Healthcare Conference being held July 13-14. Management will present a company overview on July 14 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A webcast of the presentation will be available on the NovaBay website. A.G.P.\u2019s Virtual MedTech Summer Conference featuring one-on-one investor meetings on July 29. \u201cWe are addressing extremely large markets with our two differentiated products, Avenova and CelleRx, and look forward to sharing details of our growth strategy &hellip; Continue reading \"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-08T10:53:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences","datePublished":"2021-07-08T10:53:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/"},"wordCount":837,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/","name":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-08T10:53:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210708005029r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novabay-pharmaceuticals-to-participate-in-two-july-investment-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NovaBay Pharmaceuticals to Participate in Two July Investment Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510709"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510709\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}